Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/1851
Title: An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria
Authors: Owusu-Agyei, S.
Asante, K.P.
Owusu, R.
Adjuik, M.
Amenga-Etego, S.
Dosoo, D.K.
Gyapong, J.O.
Greenwood, B.
Chandramohan, D.
Keywords: Malaria
Issue Date: 2008
Publisher: PLoS ONE
Citation: PLoS ONE | June 2008 | Volume 3 | Issue 6 | e2530
Abstract: Background: Artesunate+amodiaquine (AS+AQ) and artemether-lumefantrine (AL) are now the most frequently recommended first line treatments for uncomplicated malaria in Africa. Artesunate+chlorproguanil-dapsone (AS+CD) was a potential alternative for treatment of uncomplicated malaria. A comparison of the efficacy and safety of these three drug combinations was necessary to make evidence based drug treatment policies. Methods: Five hundred and thirty-four, glucose-6-phosphate dehydrogenase (G6PD) normal children were randomised in blocks of 15 to the AS+AQ, AL or AS+CD groups. Administration of study drugs was supervised by project staff and the children were followed up at r home on days 1,2,3,7,14 and 28 post treatment. Parasitological and clinical failures and adverse events were compared between the study groups. Main Findings: In a per-protocol analysis, the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, p = 0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, p = 0.005). In the intention to treat analysis, the rate of early treatment failure was high in all three groups (AS+AQ 13.3%; AL 15.2%; and AS+CD 9.3%, p = 0.2) primarily due to vomiting. However, the PCF28 corrected for re-infection was lower, though not significantly, in the AS+AQ group compared to the AL or the AS+CD groups (AS+AQ 18.3%; AL 24.2%; AS+CD 20.8%, p = 0.4) The incidence of adverse events was comparable between the groups. Conclusions: AS+AQ is an appropriate first line treatment for uncomplicatedmalaria in Ghana and possibly in the neighbouring countries in West Africa. The effectiveness of AL in routine programme conditions needs to be studied further in West Africa.
URI: http://hdl.handle.net/123456789/1851
Appears in Collections:School of Public Health 9

Files in This Item:
File Description SizeFormat 
Open label randomised trial of.pdf229.95 kBAdobe PDFView/Open


Items in UGSpace are protected by copyright, with all rights reserved, unless otherwise indicated.